Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;8(2):159–176. doi: 10.1111/j.1527-3458.2002.tb00221.x

Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease

Sean Lilienfeld 1,✉
PMCID: PMC6741688  PMID: 12177686

ABSTRACT

Galantamine hydrobromide is a tertiary alkaloid drug that has been developed and approved in a number of countries including the USA and several countries in Europe as a treatment for mild‐to‐moderate Alzheimer's disease (AD). Galantamine has a unique, dual mode of action. It is a reversible, competitive inhibitor of acetylcholinesterase (AChE), and is the only drug actively marketed for the treatment of AD with proven activity as an allosteric modulator of nicotinic acetylcholine receptors (nAChRs). This latter activity is thought to be particularly important since decreases in the expression and activity of nAChRs make a large contribution to the reduction in central cholinergic neurotransmission in patients with AD. Galantamine exhibits favorable pharmacokinetic characteristics including predictable linear elimination kinetics at the recommended maintenance doses (16 and 24 mg/day), a relatively short half‐life (approximately 7 h) and high bioavailability. It is extensively metabolized in numerous pathways, mainly in the liver via cytochrome P450 enzymes CYP2D6 and CYP3A4, and has a low potential for clinically significant drug‐drug interactions. During four large randomized, double‐blind, placebo‐controlled trials of up to 6 months duration, galantamine 16 and 24 mg/day significantly benefited cognitive and global function, ability to perform activities of daily living (ADL) and behavior, relative to placebo and baseline, for up to 6 months. Caregiver burden (time spent by caregivers supervising patients or assisting them with ADL), and caregiver distress (related to patients' behavioral symptoms) were also reduced. Cognitive and functional abilities were preserved at or near baseline for at least 12 months in patients who received galantamine 24 mg/day for 12 months in a long‐term US study. These benefits were maximized by early and continued galantamine treatment and, again, were associated with significant reductions in caregiver burden. Trials of the efficacy of galantamine in dementia related to cerebrovascular disease have also yielded positive results. There are no safety concerns associated with the use of galantamine. The incidence of adverse events, particularly cholinergically mediated events affecting the gastrointestinal system, is generally low and can be minimized using the recommended slow dose‐escalation scheme. Galantamine may, therefore, help to reduce the overall burden and cost involved in caring for dementia patients. Taking all evidence into account, galantamine has the potential to become a first‐line therapy for dementia.

Keywords: Galantamine, Acetylcholinesterase inhibitor, Alzheimer's disease, Nicotinic modulator

Full Text

The Full Text of this article is available as a PDF (198.5 KB).

References

  • 1. Aisen PS, Davis KL, Berg MS, et al. A randomised controlled trial of prednisone in Alzheimer's disease. Neurology 2000;54:588–593. [DOI] [PubMed] [Google Scholar]
  • 2. Albuquerque EX, Santos MD, Alkondon M, Pereira EFR, Maelicke A. Modulation of receptor activity in the central nervous system — a novel approach to the treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15 (Suppl 1): S19–S25. [DOI] [PubMed] [Google Scholar]
  • 3. Bachus R, Bickel U, Thomsen T. The O‐demethylation of the antidementia drug galantamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999;9:661–668. [PubMed] [Google Scholar]
  • 4. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000;99:17–23. [DOI] [PubMed] [Google Scholar]
  • 5. Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991;50:420–428. [DOI] [PubMed] [Google Scholar]
  • 6. Blesa R. Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000;11 (Suppl 1): 28–34. [DOI] [PubMed] [Google Scholar]
  • 7. Bosanquet N et al. Alzheimer's disease in the United Kingdom. London : Health Policy Unit, Imperial School of Medicine; 1998. [Google Scholar]
  • 8. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease — results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237–244. [DOI] [PubMed] [Google Scholar]
  • 9. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213. [DOI] [PubMed] [Google Scholar]
  • 10. Clegg A, Bryant J, Nicholson T, et al. Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease. NICE Report, January, 2001. [DOI] [PubMed]
  • 11. Court JA, Perry EK. CNS nicotinic receptors. Possible therapeutic targets in neurodegenerative disorders. CNS Drugs 1994;2:216–233. [Google Scholar]
  • 12. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48 (Suppl6): S10–S16. [DOI] [PubMed] [Google Scholar]
  • 13. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence‐based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–1166. [DOI] [PubMed] [Google Scholar]
  • 14. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet; 2002;359:1283–1290. [DOI] [PubMed] [Google Scholar]
  • 15. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52‐week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236–241. [DOI] [PubMed] [Google Scholar]
  • 16. Farlow M, Amatniek J. Managing expectations when switching Alzheimer's disease therapies. Poster presented at the 10th Congress of the International Psychogeriatric Association (IPA), Nice , France , 914 September 2001.
  • 17. Feldman H, Sauter A, Donald A, et al. The Disability Assessment for Dementia Scale: A 12‐Month Study of Functional Ability in Mild to Moderate Severity Alzheimer Disease. Alzheimer Dis Assoc Disord 2001;15:89–95. [DOI] [PubMed] [Google Scholar]
  • 18. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 (Suppl2): S33–S39. [PubMed] [Google Scholar]
  • 19. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999;53:471–481. [DOI] [PubMed] [Google Scholar]
  • 20. Janssen Pharmaceutica. Reminyl® (galantamine) tablets prescribing information. Janssen Pharmaceutica NV, 11 July 2000.
  • 21. Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health. Arch Gen Psychiatry 1999;56:848–853. [DOI] [PubMed] [Google Scholar]
  • 22. Jones RW, Cooper DM, Haworth J, et al. The effect of food on the absorption of galanthamine in healthy elderly volunteers. Br J Clin Pharmacol 1996;42:671P (bstract). [Google Scholar]
  • 23. Kerr JS, Sherwood N, Hindmarch I. Separate and combined effects of the social drugs on psychomotor performance. Psychopharmacology (Berl) 1991;104:113–119. [DOI] [PubMed] [Google Scholar]
  • 24. Kihara T, Shimohama S, Sawada H, et al. Nicotinic receptor stimulation protects neurons against beta‐amyloid toxicity. Ann Neurol 1997;42:159–163. [DOI] [PubMed] [Google Scholar]
  • 25. Kihara T, Shimohama S, Urushitani M, et al. Stimulation of α4β2 nicotinic acetylcholine receptors inhibits beta‐amyloid toxicity. Brain Res 1998;792:331–334. [DOI] [PubMed] [Google Scholar]
  • 26. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001;49:279–288. [DOI] [PubMed] [Google Scholar]
  • 27. Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer's dementia. Drug Discovery Today 1996;1:53–59. [Google Scholar]
  • 28. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11 (Suppl 1): 11–18. [DOI] [PubMed] [Google Scholar]
  • 29. Maelicke A, Schrattenholz A, Samochocki M, et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000;113:199–206. [DOI] [PubMed] [Google Scholar]
  • 30. Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl®). Int J Clin Pract 2001;Suppl 120:24–28. [PubMed] [Google Scholar]
  • 31. Marks MJ, Stitzel JA, Collins AC. Pharmacological alleviation of cholinergic lesion‐induced memory deficits in rats. Pharmacol Biochem Behav 1987;27:505–512. [DOI] [PubMed] [Google Scholar]
  • 32. Martin‐Ruiz CM, Court JA, Molnar E, et al. α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999;73:1635–1640. [DOI] [PubMed] [Google Scholar]
  • 33. McKahnn G, Drachmann D, Folstein M, et al. Clinical Diagnosis of Alzheimer's disease: report of the NICDS‐ADRDA work group under the auspices of the department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939–944. [DOI] [PubMed] [Google Scholar]
  • 34. Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J, Jovovich V. Pharmacokinetics of galantamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 1989;39:50–58. [DOI] [PubMed] [Google Scholar]
  • 35. Mulnard R, Cotman C, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA 2000;283:1007–1015. [DOI] [PubMed] [Google Scholar]
  • 36. Newhouse PA, Potter A, Corwin J, Lennox R. Age‐related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 1994;10:93–107. [DOI] [PubMed] [Google Scholar]
  • 37. Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B. Kinetic analysis of regional (S)(–) 11C‐nicotine binding in normal and Alzheimer brains —in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995;9:21–27. [DOI] [PubMed] [Google Scholar]
  • 38. Nordberg A. PET studies and cholinergic therapy in Alzheimer's disease. Rev Neurol (Paris) 1999;155 (Suppl 4): S53–S63. [PubMed] [Google Scholar]
  • 39. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Progr Neurobiol 2000;61:75–111. [DOI] [PubMed] [Google Scholar]
  • 40. Perry E, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995;64:385–395. [DOI] [PubMed] [Google Scholar]
  • 41. Proskurnina NF, Yakovleva AP. Alkaloids of Galanthus woronowi. II. Isolation of a new alkaloid [Russian]. Zh Obschchei Khim (J Gen Chem) 1952;22:1899–1902. [Google Scholar]
  • 42. Raskind MA, Peskind ER, Wessel T, Yuan W, on behalf of the Galantamine USA‐1 Study Group. Galantamine in AD — a 6‐month, randomized, placebo‐controlled trial with a 6‐month extension. Neurology 2000;54:2261–2268. [DOI] [PubMed] [Google Scholar]
  • 43. Robillard A, McKelvey R, Nasreddine Z. Galantamine improves quality of sleep in patients previously treated with donepezil (preliminary results). Poster presented at the 14th Annual Meeting of the American Association for Geriatric Psychiatry, San Francisco CA , USA , February 2326 2001.
  • 44. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. On behalf of the Galantamine International‐2 Study Group. Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. JNNP 2001;71:589–595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Rockwood K, Kershaw P. Galantamine's clinical benefits are not offset by sleep disturbance: a 3‐month placebo‐controlled study in patients with Alzheimer's disease. Poster presented at the 7th International World Alzheimer Congress, Washington DC , USA , July 2000.
  • 46. Rogers S, Friedhoff L. Long‐term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8:67–75. [DOI] [PubMed] [Google Scholar]
  • 47. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356–1364. [DOI] [PubMed] [Google Scholar]
  • 48. Rowell PP, Winkel DL. Nicotinic stimulation of [3H]acetylcholine release from mouse cerebral cortical synaposomes. J Neurochem 1984;43:1593–1598. [DOI] [PubMed] [Google Scholar]
  • 49. Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR. Acta Neurologica Scandinavica 2000;102 (Suppl 176): 68–73. [DOI] [PubMed] [Google Scholar]
  • 50. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study — Clinical Global Impression of Change, The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 (Suppl 2): S22–S32. [DOI] [PubMed] [Google Scholar]
  • 51. Schröder H, Giacobini E, Struble RG, Zilles K, Maelicke A. Nicotinic cholinoreceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 1991;12:259–262. [DOI] [PubMed] [Google Scholar]
  • 52. Smith AL, Whitehouse PJ. Progress in the management of Alzheimer's disease. Hosp Pract 1998;33:151–166. [DOI] [PubMed] [Google Scholar]
  • 53. Sramek JJ, Frackiewicz EJ, Cutler NR. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs 2000;9:2393–2402. [DOI] [PubMed] [Google Scholar]
  • 54. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5‐month, randomized, placebo‐controlled trial of galantamine in Alzheimer's disease. Neurology 2000;54:2269–2276. [DOI] [PubMed] [Google Scholar]
  • 55. Tariot PN, Truyen L. Reminyl (galantamine) reduces caregiver distress. Poster presented at the 10th Congress of the International Psychogeriatric Association (IPA), Nice , France , 914 September 2001.
  • 56. Thomsen T, Bickel U, Fischer JP, et al. Stereoselectivity of cholinesterase inhibition by galantamine and tolerance in humans. Eur J Clin Pharm 1990;39:603–605. [DOI] [PubMed] [Google Scholar]
  • 57. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991;29:487–492. [DOI] [PubMed] [Google Scholar]
  • 58. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galantamine in vitro and in vivo. Life Sci 1990;46:1553–1558. [DOI] [PubMed] [Google Scholar]
  • 59. Thomsen T, Zendeh B, Fischer JP, et al. In vitro effects of various cholinesterase inhibitors on acetyl‐ and butyryl‐cholinesterases of healthy volunteers. Biochemical Pharmacol 1991;41:139–141. [DOI] [PubMed] [Google Scholar]
  • 60. Torfs K, Feldman H. 12‐Month decline in cognitive and daily function in patients with mild‐to‐moderate Alzheimer's disease: two randomized placebo‐controlled studies. Poster presented at the World Alzheimer's Congress (WAC), Washington DC , USA , July 918 2000.
  • 61. Vizi ES, Lendavi B. Modulatory role of presynaptic nicotinic receptors in synaptic and non‐synaptic chemical communication in the central nervous system. Brain Res Rev 1999;30:219–235. [DOI] [PubMed] [Google Scholar]
  • 62. Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986;371:146–151. [DOI] [PubMed] [Google Scholar]
  • 63. Wilcock G, Lilienfeld S. Galantamine alleviates caregiver burden in Alzheimer's disease: a 6‐month placebo‐controlled study. Poster presented at the World Alzheimer's Congress (WAC), Washington DC , USA , July 918, 2000.
  • 64. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International‐1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: a multicentre randomised controlled trial. BMJ 2000;321:1445–1449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's disease; pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995;51:509–514. [DOI] [PubMed] [Google Scholar]
  • 66. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success Int J Geriatr Psych 2001;16:653–666. [DOI] [PubMed] [Google Scholar]
  • 67. Zhao Q, Lyver G, Lee P, Parier J, Pesco‐Koplowitz L. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers J Clin Pharmacol 2001. (submitted) . [PubMed] [Google Scholar]
  • 68. Zhao Q, Brett M, Van Osselaer N, et al. Similar pharmacokinetics for galantamine in healthy Caucasian and Japanese subjects. J Clin Pharmacol 2001. (submitted) . [PubMed] [Google Scholar]
  • 69. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP. Increased neurodegeneration during ageing in mice lacking high‐affinity nicotine receptors. EMBO J 1999;18:1235–1244. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES